ClinicalTrials.gg
CompletedNCT00738842Updated Dec 3, 2010

Uric Acid Study in Healthy Male Volunteers

A Phase 1 interventional study of AZD6140 and Placebo to match AZD6140 in Gout and Coronary Artery Disease, sponsored by AstraZeneca. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-03.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Gout by AstraZeneca — none open to participants now, none under way, none of them phase 3. Gout · AstraZeneca.

Enrollment
21st of 24
24 · median 87
Started
2008
the only one that year
Phase 1
9 of 27
none open now
Registered
1st of 27
by date

Among the 27 studies in Gout by AstraZeneca, this one is the 21st largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2008, is one of 9 in phase 1, and was the 1st registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

None of the 27 studies in Gout by AstraZeneca is open now. The open studies under Gout, anywhere →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies in Gout by AstraZeneca as a file.
02

Study summary

This study is being conducted to examine the effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.

03

Conditions studied

  • Gout
  • Coronary Artery Disease

Keywords

  • Uric
  • Acid
  • Level
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal physical examination, vital signs, (ECG) and laboratory values (unless the investigator considers an abnormality not to be )
  • Normal laboratory tests at screening
  • Non-smoker (no cigarette/tobacco use for at least 6 months)

Exclusion criteria

Exclusion Criteria:

  • Personal or family history of gout, gouty arthritis, or renal stones
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    1

    Drug: AZD6140

  • Placebo comparator
    2

    Drug: Placebo to match AZD6140

Interventions

  • Oral tablets taken bid for 5 days

  • DrugPlacebo to match AZD6140

    Oral tablets taken bid for 5 days

06

What researchers measure

Primary outcomes

  1. The effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.

    Time frame: Levels or certain chemicals in subjects' blood and urine will be measured at scheduled times during the first 7 days of the study.

Secondary outcomes

  1. The blood levels of AZD6140 in various subjects on the same diet.

    Time frame: following dosing during the first 5 days of the study

  2. The effect of taking AZD6140 on the levels of certain hormones in urine

    Time frame: during the first 5 days of the study

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2008
First posted
Aug 21, 2008
Start
May 2008
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Last update
Dec 3, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00738842
Lead sponsor
AstraZeneca
First posted
Aug 21, 2008
Start date
May 2008
Primary completion
Jul 2008
Completion
Jul 2008
Last update
Dec 3, 2010

Study contacts

Kathleen Butler, MD
study director · AstraZeneca
Stuart Harris, MD
principal investigator · SeaView Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion